Effect of glucosamine on expression of type II collagen, matrix metalloproteinase and sirtuin genes in a human chondrocyte cell line

Igarashi,Mamoru; Sakamoto,Koji; Nagaoka,Isao

doi:10.3892/ijmm.2016.2842

Effect of glucosamine on expression of type II collagen, matrix metalloproteinase and sirtuin genes in a human chondrocyte cell line

Authors:
- Mamoru Igarashi
- Koji Sakamoto
- Isao Nagaoka
View Affiliations

Affiliations: Department of Host Defense and Biochemical Research, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan
Published online on: December 28, 2016 https://doi.org/10.3892/ijmm.2016.2842
Pages: 472-478

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glucosamine (GlcN) has been widely used to treat osteoarthritis (OA) in humans. However, the effects of GlcN on genes related to cartilage metabolism are still unknown. In the present study, to elucidate the chondroprotective action of GlcN on OA, we examined the effects of GlcN (0.1-10 mM) on the expression of the sirtuin (SIRT) genes as well as type II collagen and matrix metalloproteinases (MMPs) using a human chondrocyte cell line SW 1353. SW 1353 cells were incubated in the absence or presence of GlcN. RT-PCR analyses revealed that GlcN markedly increased the mRNA expression of type II collagen (COL2A1). By contrast, the levels of MMP-1 and MMP-9 mRNA were only slightly increased by GlcN. Furthermore, western blot analyses revealed that GlcN significantly increased the protein level of COL2A1. Importantly, GlcN enhanced the mRNA expression and protein level of SIRT1, an upstream-regulating gene of COL2A1. Moreover, a SIRT1 inhibitor suppressed GlcN-induced COL2A1 gene expression. Together these observations suggest that GlcN enhances the mRNA expression and protein level of SIRT1 and its downstream gene COL2A1 in chondrocytes, thereby possibly exhibiting chondroprotective action on OA.

View Figures

View References

1	Hunter DJ and Felson DT: Osteoarthritis. BMJ. 332:639–642. 2006. View Article : Google Scholar : PubMed/NCBI
2	Gabriel SE, Crowson CS, Campion ME and O'Fallon WM: Direct medical costs unique to people with arthritis. J Rheumatol. 24:719–725. 1997.PubMed/NCBI
3	March LM and Bachmeier CJ: Economics of osteoarthritis: a global perspective. Baillieres Clin Rheumatol. 11:817–834. 1997. View Article : Google Scholar
4	Loeser RF: Age-related changes in the musculoskeletal system and the development of osteoarthritis. Clin Geriatr Med. 26:371–386. 2010. View Article : Google Scholar : PubMed/NCBI
5	Goldring MB: The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res. 40:1–11. 1999. View Article : Google Scholar
6	Crolle G and D'Este E: Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin. 7:104–109. 1980. View Article : Google Scholar : PubMed/NCBI
7	Drovanti A, Bignamini AA and Rovati AL: Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo-controlled double-blind investigation. Clin Ther. 3:260–272. 1980.PubMed/NCBI
8	Tapadinhas MJ, Rivera IC and Bignamini AA: Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica. 3:157–168. 1982.PubMed/NCBI
9	Lopes Vaz A: Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res Opin. 8:145–149. 1982. View Article : Google Scholar : PubMed/NCBI
10	McAlindon TE, LaValley MP, Gulin JP and Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 283:1469–1475. 2000. View Article : Google Scholar : PubMed/NCBI
11	Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE and Gossett C: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 357:251–256. 2001. View Article : Google Scholar : PubMed/NCBI
12	Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G and Rovati LC: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 162:2113–2123. 2002. View Article : Google Scholar : PubMed/NCBI
13	Igarashi M, Kaga I, Takamori Y, Sakamoto K, Miyazawa K and Nagaoka I: Effects of glucosamine derivatives and uronic acids on the production of glycosaminoglycans by human synovial cells and chondrocytes. Int J Mol Med. 27:821–827. 2011.PubMed/NCBI
14	Loeser RF: Molecular mechanisms of cartilage destruction: mechanics, inflammatory mediators, and aging collide. Arthritis Rheum. 54:1357–1360. 2006. View Article : Google Scholar : PubMed/NCBI
15	Abramson SB, Attur M and Yazici Y: Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol. 2:304–312. 2006. View Article : Google Scholar : PubMed/NCBI
16	Goldring MB and Goldring SR: Osteoarthritis. J Cell Physiol. 213:626–634. 2007. View Article : Google Scholar : PubMed/NCBI
17	Attur M, Krasnokutsky-Samuels S, Samuels J and Abramson SB: Prognostic biomarkers in osteoarthritis. Curr Opin Rheumatol. 25:136–144. 2013. View Article : Google Scholar :
18	Li Y, Tsun A, Gao Z, Han Z, Gao Y, Li Z, Lin F, Wang Y, Wei G, Yao Z, et al: 60-kDa Tat-interactive protein (TIP60) positively regulates Th-inducing POK (ThPOK)-mediated repression of eomesodermin in human CD4⁺ T cells. J Biol Chem. 288:15537–15546. 2013. View Article : Google Scholar : PubMed/NCBI
19	Hattori T, Kubota S, Yutani Y, Fujisawa T, Nakanishi T, Takahashi K and Takigawa M: Change in cellular localization of a rheumatoid arthritis-related antigen (RA-A47) with downregulation upon stimulation by inflammatory cytokines in chondrocytes. J Cell Physiol. 186:268–281. 2001. View Article : Google Scholar : PubMed/NCBI
20	Neumann C, Yu A, Welge-Lüssen U, Lütjen-Drecoll E and Birke M: The effect of TGF-beta2 on elastin, type VI collagen, and components of the proteolytic degradation system in human optic nerve astrocytes. Invest Ophthalmol Vis Sci. 49:1464–1472. 2008. View Article : Google Scholar : PubMed/NCBI
21	Kim SO and Kim MR: [6]-Gingerol prevents disassembly of cell junctions and activities of MMPs in invasive human pancreas cancer cells through ERK/NF-κB/Snail signal transduction pathway. Evid Based Complement Alternat Med. 2013:7618522013. View Article : Google Scholar
22	Liacini A, Sylvester J, Li WQ, Huang W, Dehnade F, Ahmad M and Zafarullah M: Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res. 288:208–217. 2003. View Article : Google Scholar : PubMed/NCBI
23	Shah ZH, Ahmed SU, Ford JR, Allison SJ, Knight JRP and Milner J: A deacetylase-deficient SIRT1 variant opposes full-length SIRT1 in regulating tumor suppressor p53 and governs expression of cancer-related genes. Mol Cell Biol. 32:704–716. 2012. View Article : Google Scholar :
24	Ji S, Doucette JR and Nazarali AJ: Sirt2 is a novel in vivo downstream target of Nkx2.2 and enhances oligodendroglial cell differentiation. J Mol Cell Biol. 3:351–359. 2011. View Article : Google Scholar : PubMed/NCBI
25	Grubisha O, Rafty LA, Takanishi CL, Xu X, Tong L, Perraud AL, Scharenberg AM and Denu JM: Metabolite of SIR2 reaction modulates TRPM2 ion channel. J Biol Chem. 281:14057–14065. 2006. View Article : Google Scholar : PubMed/NCBI
26	Song R, Xu W, Chen Y, Li Z, Zeng Y and Fu Y: The expression of sirtuins 1 and 4 in peripheral blood leukocytes from patients with type 2 diabetes. Eur J Histochem. 55:e102011. View Article : Google Scholar : PubMed/NCBI
27	Orecchia A, Scarponi C, Di Felice F, Cesarini E, Avitabile S, Mai A, Mauro ML, Sirri V, Zambruno G, Albanesi C, et al: Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. PLoS One. 6:e243072011. View Article : Google Scholar : PubMed/NCBI
28	Kanfi Y, Shalman R, Peshti V, Pilosof SN, Gozlan YM, Pearson KJ, Lerrer B, Moazed D, Marine JC, de Cabo R, et al: Regulation of SIRT6 protein levels by nutrient availability. FEBS Lett. 582:543–548. 2008. View Article : Google Scholar : PubMed/NCBI
29	Dvir-Ginzberg M, Gagarina V, Lee EJ and Hall DJ: Regulation of cartilage-specific gene expression in human chondrocytes by SirT1 and nicotinamide phosphoribosyltransferase. J Biol Chem. 283:36300–36310. 2008. View Article : Google Scholar : PubMed/NCBI
30	Gray SG and Ekström TJ: The human histone deacetylase family. Exp Cell Res. 262:75–83. 2001. View Article : Google Scholar : PubMed/NCBI
31	Gertz M, Fischer F, Nguyen GTT, Lakshminarasimhan M, Schutkowski M, Weyand M and Steegborn C: Ex-527 inhibits sirtuins by exploiting their unique NAD⁺-dependent deacetylation mechanism. Proc Natl Acad Sci USA. 110:E2772–E2781. 2013. View Article : Google Scholar
32	Nagaoka I, Igarashi M and Sakamoto K: Biological activities of glucosamine and its related substances. Adv Food Nutr Res. 65:337–352. 2012. View Article : Google Scholar : PubMed/NCBI
33	Bhosale AM and Richardson JB: Articular cartilage: structure, injuries and review of management. Br Med Bull. 87:77–95. 2008. View Article : Google Scholar : PubMed/NCBI
34	Eyre DR: Collagens and cartilage matrix homeostasis. Clin Orthop Relat Res. 427(Suppl): S118–S122. 2004. View Article : Google Scholar
35	Eyre DR, Weis MA and Wu JJ: Articular cartilage collagen: an irreplaceable framework? Eur Cell Mater. 12:57–63. 2006. View Article : Google Scholar : PubMed/NCBI
36	Block JA, Oegema TR, Sandy JD and Plaas A: The effects of oral glucosamine on joint health: is a change in research approach needed? Osteoarthritis Cartilage. 18:5–11. 2010. View Article : Google Scholar
37	Varghese S, Theprungsirikul P, Sahani S, Hwang N, Yarema KJ and Elisseeff JH: Glucosamine modulates chondrocyte proliferation, matrix synthesis, and gene expression. Osteoarthritis Cartilage. 15:59–68. 2007. View Article : Google Scholar
38	Derfoul A, Miyoshi AD, Freeman DE and Tuan RS: Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. Osteoarthritis Cartilage. 15:646–655. 2007. View Article : Google Scholar : PubMed/NCBI
39	Stoppoloni D, Politi L, Leopizzi M, Gaetani S, Guazzo R, Basciani S, Moreschini O, De Santi M, Scandurra R and Scotto d'Abusco A: Effect of glucosamine and its peptidyl-derivative on the production of extracellular matrix components by human primary chondrocytes. Osteoarthritis Cartilage. 23:103–113. 2015. View Article : Google Scholar
40	Gabay O, Oppenhiemer H, Meir H, Zaal K, Sanchez C and Dvir-Ginzberg M: Increased apoptotic chondrocytes in articular cartilage from adult heterozygous SirT1 mice. Ann Rheum Dis. 71:613–616. 2012. View Article : Google Scholar : PubMed/NCBI
41	Matsuzaki T, Matsushita T, Takayama K, Matsumoto T, Nishida K, Kuroda R and Kurosaka M: Disruption of Sirt1 in chondrocytes causes accelerated progression of osteoarthritis under mechanical stress and during ageing in mice. Ann Rheum Dis. 73:1397–1404. 2014. View Article : Google Scholar
42	Gabay O, Sanchez C, Dvir-Ginzberg M, Gagarina V, Zaal KJ, Song Y, He XH and McBurney MW: Sirtuin 1 enzymatic activity is required for cartilage homeostasis in vivo in a mouse model. Arthritis Rheum. 65:159–166. 2013. View Article : Google Scholar
43	Hong EH, Lee SJ, Kim JS, Lee KH, Um HD, Kim JH, Kim SJ, Kim JI and Hwang SG: Ionizing radiation induces cellular senescence of articular chondrocytes via negative regulation of SIRT1 by p38 kinase. J Biol Chem. 285:1283–1295. 2010. View Article : Google Scholar :
44	Takayama K, Ishida K, Matsushita T, Fujita N, Hayashi S, Sasaki K, Tei K, Kubo S, Matsumoto T, Fujioka H, et al: SIRT1 regulation of apoptosis of human chondrocytes. Arthritis Rheum. 60:2731–2740. 2009. View Article : Google Scholar : PubMed/NCBI
45	Gagarina V, Gabay O, Dvir-Ginzberg M, Lee EJ, Brady JK, Quon MJ and Hall DJ: SirT1 enhances survival of human osteoarthritic chondrocytes by repressing protein tyrosine phosphatase 1B and activating the insulin-like growth factor receptor pathway. Arthritis Rheum. 62:1383–1392. 2010. View Article : Google Scholar : PubMed/NCBI
46	Fujita N, Matsushita T, Ishida K, Kubo S, Matsumoto T, Takayama K, Kurosaka M and Kuroda R: Potential involvement of SIRT1 in the pathogenesis of osteoarthritis through the modulation of chondrocyte gene expressions. J Orthop Res. 29:511–515. 2011. View Article : Google Scholar : PubMed/NCBI
47	Moon MH, Jeong JK, Lee YJ, Seol JW, Jackson CJ and Park SY: SIRT1, a class III histone deacetylase, regulates TNF-α-induced inflammation in human chondrocytes. Osteoarthritis Cartilage. 21:470–480. 2013. View Article : Google Scholar
48	Matsushita T, Sasaki H, Takayama K, Ishida K, Matsumoto T, Kubo S, Matsuzaki T, Nishida K, Kurosaka M and Kuroda R: The overexpression of SIRT1 inhibited osteoarthritic gene expression changes induced by interleukin-1β in human chondrocytes. J Orthop Res. 31:531–537. 2013. View Article : Google Scholar
49	Wells L, Whelan SA and Hart GW: O-GlcNAc: a regulatory post-translational modification. Biochem Biophys Res Commun. 302:435–441. 2003. View Article : Google Scholar : PubMed/NCBI
50	Love DC and Hanover JA: The hexosamine signaling pathway: deciphering the 'O-GlcNAc code'. Sci STKE. 2005:re132005.
51	Chou TY, Dang CV and Hart GW: Glycosylation of the c-Myc transactivation domain. Proc Natl Acad Sci USA. 92:4417–4421. 1995. View Article : Google Scholar : PubMed/NCBI
52	Han I and Kudlow JE: Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol. 17:2550–2558. 1997. View Article : Google Scholar : PubMed/NCBI
53	Jiang MS and Hart GW: A subpopulation of estrogen receptors are modified by O-linked N-acetylglucosamine. J Biol Chem. 272:2421–2428. 1997. View Article : Google Scholar : PubMed/NCBI
54	Yang WH, Kim JE, Nam HW, Ju JW, Kim HS, Kim YS and Cho JW: Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol. 8:1074–1083. 2006. View Article : Google Scholar : PubMed/NCBI
55	Fujiki R, Hashiba W, Sekine H, Yokoyama A, Chikanishi T, Ito S, Imai Y, Kim J, He HH, Igarashi K, et al: GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature. 480:557–560. 2011.PubMed/NCBI
56	Ju Y, Hua J, Sakamoto K, Ogawa H and Nagaoka I: Glucosamine, a naturally occurring amino monosaccharide modulates LL-37-induced endothelial cell activation. Int J Mol Med. 22:657–662. 2008.PubMed/NCBI
57	Ju Y, Hua J, Sakamoto K, Ogawa H and Nagaoka I: Modulation of TNF-alpha-induced endothelial cell activation by glucosamine, a naturally occurring amino monosaccharide. Int J Mol Med. 22:809–815. 2008.PubMed/NCBI
58	Someya A, Sakamoto K and Nagaoka I: Glucosamine induces the O-N-acetylglucosamine modification of transcription factor Sp1. Glucosamine Res. 9:48–52. 2013.